Jill DeSimone - Mar 1, 2023 Form 4 Insider Report for Kinnate Biopharma Inc. (KNTE)

Role
Director
Signature
/s/ Mark A. Meltz, attorney in fact
Stock symbol
KNTE
Transactions as of
Mar 1, 2023
Transactions value $
$0
Form type
4
Date filed
3/3/2023, 04:54 PM
Previous filing
Jan 5, 2023
Next filing
Jun 14, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNTE Stock Option (right to buy) Award $0 +50K $0.00 50K Mar 1, 2023 Common Stock 50K $5.21 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/36th of the shares underlying the Option vest and become exercisable on each monthly anniversary of the Date of Grant.